(Q41863259)

English

A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy

scientific article published on September 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy (English)

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

phase II clinical trial

0 references

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Sunil Sharma

1

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

James Symanowski

2

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Bryan Wong

3

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Pamela Dino

4

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Phillip Manno

5

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Nicholas Vogelzang

6

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

publication date

1 September 2008

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Translational Oncology

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

1

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

3

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

141-147

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

5 June 2018

Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

5 June 2018

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

5 June 2018

Histone deacetylase inhibitors in programmed cell death and cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

5 June 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

5 June 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

5 June 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

5 June 2018

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

5 June 2018

Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

5 June 2018

Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

5 June 2018

Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

5 June 2018

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

5 June 2018

Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

5 June 2018

Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

5 June 2018

Morphological reversion of sis-transformed NIH3T3 cells by trichostatin A.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

5 June 2018

A novel tetracyclic peptide, trapoxin, induces phenotypic change from transformed to normal in sis-oncogene-transformed NIH3T3 cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

5 June 2018

5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

3 July 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

18 August 2018

Histone deacetylase is a target of valproic acid-mediated cellular differentiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

18 August 2018

Trichostatin A Induces Morphological Changes and Gelsolin Expression by Inhibiting Histone Deacetylase in Human Carcinoma Cell Lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2533142

2 December 2018

Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New paradigms for advanced prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DNA methylation properties: consequences for pharmacology

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversible arrest of proliferation of rat 3Y1 fibroblasts in both the G1 and G2 phases by trichostatin A

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of trichostatins on differentiation of murine erythroleukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18795124

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.43.1524

Identifiers

10.1593/TLO.08136

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41863259&oldid=2127458914"